Status:
COMPLETED
Trial of L-DOPA as a Treatment to Improve Vision in Albinism
Lead Sponsor:
University of Minnesota
Conditions:
Albinism
Eligibility:
All Genders
3-60 years
Phase:
PHASE2
Brief Summary
This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism....
Detailed Description
A group of 45 individuals with the clinical findings of oculocutaneous albinism (OCA) will be randomly assigned to one of 3 treatment groups: treatment with 0.76 mg/kg/d with 25% carbidopa, 0.51 mg/kg...
Eligibility Criteria
Inclusion
- Age 3 to 60 years with albinism
Exclusion
- Glaucoma or at increased risk of glaucoma
- History of dystonia
- History of melanoma
- Planning to undergo eye muscle surgery during study time frame
- Undergoing vision therapy
- Taking iron supplements or vitamins with iron
- Taking medication for ADHD
- Known liver or gastrointestinal disease
- Previous treatment with levodopa
- Psychological problems
- Ocular abnormalities other than those associated with albinism
- Pregnant, nursing or planning to become pregnant during study
- Known allergy to levodopa/carbidopa
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT01176435
Start Date
September 1 2010
End Date
December 1 2014
Last Update
May 2 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota Eye Clinic
Minneapolis, Minnesota, United States, 55455